Company intelligence / Profile preview

Novelus Biotechnology

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Novellus Therapeutics was a precision oncology biotechnology company focused on developing next-generation therapies for cancer patients with specific genetic mutations. The company utilized its proprietary REGEN mRNA-based cell reprogramming platform to discover and develop novel therapeutic candidates. Novellus specialized in identifying and targeting rare driver mutations in oncology, such as specific BRAF and KRAS variants, that were underserved by existing treatments. In July 2021, the company was acquired by Brooklyn ImmunoTherapeutics (now Eterna Therapeutics) to integrate its mRNA technology and oncology pipeline into a broader cell therapy portfolio.

Therapeutic areas: Oncology
Modalities: mRNA-based drugsCell therapySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Novelus Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novelus Biotechnology.

Explore the full profile